Medicare Enrolled
Dr. Joyce O'Shaughnessy, MD
Medical Oncology · Dallas, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. O'Shaughnessy from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. O'Shaughnessy? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. O'Shaughnessy
Dr. Joyce O'Shaughnessy is a medical oncology in Dallas, TX, with 19 years in practice. Based on federal Medicare data, Dr. O'Shaughnessy performed 111,460 Medicare services across 3,907 unique beneficiaries.
Between the years covered by Open Payments, Dr. O'Shaughnessy received a total of $1,378,319 from 53 pharmaceutical and/or device companies across 839 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. O'Shaughnessy is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 8% volume in TX$ $1,378,319 industry payments
Medicare Practice Summary
Medicare Utilization ↗111,460
Medicare services
Top 8% in TX for medical oncology
3,907
Unique beneficiaries
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,866 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 25,900 | $43 | $137 |
| Anti-nausea injection (fosaprepitant) | 15,300 | $0 | $5 |
| Paclitaxel chemotherapy injection | 12,375 | $0 | $8 |
| Contrast dye for imaging (iodine-based) | 11,825 | $0 | $3 |
| Iron infusion (Feraheme) | 11,220 | $0 | $5 |
| Denosumab injection (Prolia/Xgeva) | 6,540 | $18 | $66 |
| Daratumumab injection (Darzalex) | 5,040 | $38 | $127 |
| Iron sucrose injection (Venofer) | 3,900 | $0 | $2 |
| Injection, lanreotide, 1 mg | 3,240 | $46 | $227 |
| Dexamethasone injection (steroid) | 3,105 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,610 | $1 | $114 |
| Injection, granisetron hydrochloride, 100 mcg | 1,430 | $0 | $24 |
| Injection, fulvestrant, 25 mg | 830 | $8 | $244 |
| Comprehensive metabolic blood panel | 792 | $10 | $64 |
| Blood draw (venipuncture) | 777 | $8 | $20 |
| Complete blood count (CBC) with differential | 738 | $8 | $36 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 592 | $23 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 486 | $104 | $707 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 428 | $3 | $373 |
| Injection, leucovorin calcium, per 50 mg | 406 | $3 | $25 |
| Injection of additional new drug or substance into vein | 394 | $12 | $108 |
| Injection, carboplatin, 50 mg | 351 | $2 | $300 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 331 | $20 | $128 |
| Carcinoembryonic antigen (cea) protein level | 329 | $19 | $99 |
| Injection, fluorouracil, 500 mg | 310 | $2 | $13 |
| Office visit, established patient, complex (40-54 min) | 258 | $134 | $496 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 240 | $74 | $1,348 |
| Injection, zoledronic acid, 1 mg | 240 | $7 | $431 |
| Injection, magnesium sulfate, per 500 mg | 200 | $1 | $6 |
| Administration of additional new drug or substance into vein, 1 hour or less | 166 | $52 | $344 |
| Injection, diphenhydramine hcl, up to 50 mg | 165 | $1 | $7 |
| Chest X-ray, 2 views | 146 | $16 | $61 |
| Drug injection, under skin or into muscle | 133 | $11 | $96 |
| Office visit, established patient (30-39 min) | 132 | $94 | $368 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 131 | $51 | $313 |
| Ct scan of chest with contrast | 118 | $56 | $821 |
| Unclassified drugs | 118 | $3 | $15 |
| Injection, cisplatin, powder or solution, 10 mg | 109 | $2 | $94 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 97 | $27 | $145 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 91 | $56 | $211 |
| CT scan of abdomen and pelvis with contrast | 88 | $185 | $1,067 |
| Infusion, normal saline solution , 1000 cc | 80 | $2 | $19 |
| Administration of chemotherapy into vein, each additional hour | 68 | $22 | $161 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 67 | $16 | $94 |
| Microscopic examination for white blood cells with manual cell count | 48 | $4 | $22 |
| Complete blood count (CBC), automated | 48 | $6 | $34 |
| Administration of additional new drug or substance into vein using push technique | 41 | $43 | $289 |
| New patient office visit, complex (60-74 min) | 40 | $167 | $709 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 38 | $16 | $100 |
| Infusion into a vein for hydration, each additional hour | 35 | $10 | $75 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 35 | $1 | $19 |
| Iron level test | 34 | $6 | $27 |
| Administration of chemotherapy into vein using push technique | 33 | $81 | $500 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 30 | $1,148 | $4,802 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 29 | $135 | $500 |
| CT scan of chest, without contrast | 28 | $51 | $686 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 28 | $88 | $657 |
| Hospital follow-up visit, high complexity | 19 | $94 | $357 |
| Application of on-body injector for under skin injection | 18 | $14 | $96 |
| Urinalysis with microscopic exam | 17 | $3 | $28 |
| Reticulated (young) platelet measurement | 15 | $35 | $143 |
| Ct scan of soft tissue of neck with contrast | 14 | $62 | $658 |
| Ct scan of abdomen and pelvis without contrast | 14 | $87 | $560 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
11.0% high complexity
85.4% medium
3.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,378,319
Total received (2018-2024)
Avg $196,903/year across 7 years
Top 2% in TX for medical oncology
53
Companies
839
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,060,907 (77.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$272,261 (19.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$44,150 (3.2%)
Other
Charitable contributions, space rental, and other categories
$1,000 (0.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$116,999
2023$321,711
2022$179,313
2021$219,821
2020$143,166
2019$229,965
2018$167,344
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Lilly USA, LLC
$259,236
Merck Sharp & Dohme LLC
$108,682
Seagen Inc.
$105,434
AstraZeneca Pharmaceuticals LP
$102,788
AstraZeneca UK Limited
$97,427
F. Hoffmann-La Roche AG
$86,733
PFIZER INC.
$80,644
Novartis Pharmaceuticals Corporation
$68,399
Eli Lilly and Company
$53,606
Merck Sharp & Dohme Corporation
$51,191
Eisai Co., Ltd.
$34,553
Stemline Therapeutics Inc.
$32,722
Puma Biotechnology, Inc.
$27,518
NOVARTIS PHARMACEUTICALS CORPORATION
$26,117
GENZYME CORPORATION
$22,016
AbbVie, Inc.
$20,324
Novartis Pharma AG
$18,515
Gilead Sciences, Inc.
$15,094
Amgen Inc.
$14,668
BioNTech SE
$13,539
Genentech USA, Inc.
$13,086
SANOFI-AVENTIS U.S. LLC
$12,835
JAZZ PHARMACEUTICALS INC.
$10,234
TerSera Therapeutics LLC
$9,217
Eisai Inc.
$8,859
Daiichi Sankyo Inc.
$8,035
Sandoz Inc.
$7,500
G1 Therapeutics, Inc.
$6,730
Seattle Genetics, Inc.
$6,488
Celgene Corporation
$6,150
Genentech, Inc.
$5,663
Davol Inc.
$5,558
PUMA BIOTECHNOLOGY, INC.
$4,762
Athenex Pharmaceutical Division, LLC
$4,375
Sirtex Medical Inc
$3,220
Incyte Corporation
$3,075
Blueprint Medicines Corporation
$2,746
Foundation Medicine, Inc.
$2,615
Janssen Research & Development, LLC
$2,400
Taiho Oncology, Inc.
$2,100
GlaxoSmithKline, LLC.
$1,950
AbbVie Inc.
$1,925
Samsung Bioepis Co., Ltd.
$1,750
EISAI INC.
$1,360
Aadi Bioscience, Inc.
$1,350
SANOFI US SERVICES INC.
$938
Halozyme Inc
$900
Dompe US, Inc.
$800
Eagle Pharmaceuticals, Inc.
$600
E.R. Squibb & Sons, L.L.C.
$550
Ipsen Bioscience Inc
$480
Partner Therapeutics, Inc.
$450
Roche Products Limited
$414
Top 3 companies account for 34.3% of total payments
Associated products mentioned in payments ›
Abraxane · BOSULIF · BYL719 · COSELA · ENHERTU · Enhertu · FOUNDATIONONE CDX · Fyarro · Halaven · Herceptin · IBRANCE · IMFINZI · Itovebi · KEYTRUDA · KISQALI · LEE011 · LEE011H_KISQALI_ONCOLOGY · LUMAKRAS · LYNPARZA · Lenvima · Leukine · NERLYNX · Nerlynx · Non-Covered Product · ONTRUZANT · Oral Paclitaxel · Orserdu · PIQRAY · Perjeta · Phesgo · Ryanodex Single Use Only - 250ml · SIR-Spheres Microspheres · TECENTRIQ · TUKYSA · Trodelvy · Truqap · VERZENIO · XGEVA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (77%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 2% for medical oncology in TX.
Equivalent to $1,237 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
90
Per 100K population
3.5
County median income
$74,149
Nearest hospital
BAYLOR UNIVERSITY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. O'Shaughnessy is a mixed practice specialist, with above-average Medicare volume (top 8% in TX), and high industry engagement (consulting-driven, top 2%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. O'Shaughnessy experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. O'Shaughnessy performed 25,900 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. O'Shaughnessy receive payments from pharmaceutical companies?
Yes. Dr. O'Shaughnessy received a total of $1,378,319 from 53 companies across 839 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. O'Shaughnessy's costs compare to other medical oncologys in Dallas?
Dr. O'Shaughnessy's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. O'Shaughnessy) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Dallas
Browse medical oncologys in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
By company
Seagen Inc. Payments to Doctors
See all physicians who received payments from Seagen Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology